Advertisement


Rami Manochakian, MD, on NSCLC: Clinical Implications of Findings on Nivolumab Plus Chemotherapy

2022 ASCO Annual Meeting

Advertisement

Rami Manochakian, MD, of Mayo Clinic Florida, discusses the phase II findings of the NADIM II trial, which confirmed that, in terms of pathologic complete response as well as the feasibility of surgery, combining nivolumab and chemotherapy was superior to chemotherapy alone as a neoadjuvant treatment for locally advanced, resectable stage IIIA non–small cell lung cancer (Abstract 8501).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The NADIM II Trial is a randomized open label Phase II trial of Neoadjuvant Nivolumab with a regimen, chemotherapy regimen, of carboplatin paclitaxel versus chemotherapy alone, given in three cycles for patients with Stage 3A non-small cell lung cancer. After the three cycle of the neoadjuvant therapy, patient proceeded with surgery, and following surgery, patient received six months of Adjuvant Nivolumab. This study was done by the Spanish Lung Cancer Group Trial. The study primary endpoint was the pathological complete response rate, and secondary endpoint, there was the major pathological response rate, as well as response rate and also adverse events. This study is important, since it's really looking in particular at the Stage 3A patients with non-small cell lung cancer. This is a challenging population. There is an evolving research and trials testing in particularly this population. We have recently reported CheckMate 816, that led to the approval of Neoadjuvant Nivolumab and chemotherapy in patients from Stage 1B to Stage 3. We have the Adjuvant therapy also approved in a patient with Stage 3. We have the patient who don't undergo resection, and they receive concurrent chemoradiation. So, what this trial is come as a validation to the CheckMate 816, looking in particularly to this patient of a Stage 3A. The result of the studies were positive. The primary endpoint, which was the pathological complete response rate, was about 36% versus 7% in the patients who did not get the immunotherapy and received the chemotherapy alone. The secondary endpoint, the major pathological response rate, which means the 10% or less of viable tumor in the resected specimen and lymph node, was 52% versus 13%. The overall response rate was 74% versus 48%. And the adverse event, there was some modest increase in the adverse event, in particularly the Grade 3, 4. It was about 24% versus 20%. This study is, again, comes as a validation for the role of Neoadjuvant chemotherapy and immunotherapy in patient with Stage 3A. This is something that has continued to evolve, as I mentioned earlier, and it's definitely set a standard of care option as one of the option for patients who potentially have resectable Stage 3 non-small cell lung cancer to receive chemotherapy and immunotherapy, followed by surgery and followed by Adjuvant immunotherapy.

Related Videos

Breast Cancer

Stephanie Walker on Increasing the Participation of Black Women With Metastatic Breast Cancer in Clinical Trials

Stephanie Walker, a former nurse and current activist with the Metastatic Breast Cancer Alliance, discusses findings from the BECOME project (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement). They show that, even though Black patients comprise between 4% and 6% of all clinical trial participants, Black women with metastatic breast cancer are willing to consider taking part if steps were taken to increase their awareness, build trust through clear communication with health-care providers, involve people of shared racial/ethnic identity and health experience, and help patients find and access trials (Abstract 1014).

Bladder Cancer
Immunotherapy

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Long-Term Outcomes With Enfortumab Vedotin-ejfv vs Chemotherapy

Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss the 24-month findings from the phase III EV-301 trial, which suggest that enfortumab vedotin-ejfv continues to show a significant and consistent survival advantage over standard chemotherapy in patients with previously treated advanced urothelial carcinoma (Abstract 4516).

Sarcoma

Martin McCabe, PhD, on Ewing Sarcoma: Assessment of Topotecan, Cyclophosphamide, and High-Dose Ifosfamide

Martin McCabe, PhD, of the University of Manchester, discusses a phase III assessment of chemotherapy for patients with recurrent and primary refractory Ewing sarcoma. The trial, called rEECur, is the first study to provide comparative toxicity and survival data for the four most commonly used chemotherapy regimens in this disease. The analysis showed that high-dose ifosfamide is more effective in prolonging survival than topotecan plus cyclophosphamide (Abstract LBA2).

Issues in Oncology
Global Cancer Care

Clifford A. Hudis, MD, and Karen E. Knudsen, PhD, MBA, on How ASCO and the American Cancer Society Are Collaborating to Help Patients With Cancer

Clifford A. Hudis, MD, of the American Society of Clinical Oncology, and Karen E. Knudsen, PhD, MBA, of the American Cancer Society, discuss their collaboration, pooling their research and education resources to help empower patients with cancer and their families. Within 48 hours, Drs. Hudis and Knudsen were able to gear up a rapid response to the crisis in Ukraine, forming a clinical corps of volunteers to post information online in multiple languages, which helped patients navigate their care in the war-torn region. To date, 300 European cancer organizations have joined their efforts.

Supportive Care
Symptom Management

Sriram Yennu, MD, on Cancer-Related Fatigue: Is Open-Labeled Placebo an Effective Treatment?

Sriram Yennu, MD, of The University of Texas MD Anderson Cancer Center, discusses the placebo response in patients with advanced cancer and cancer-related fatigue. His latest findings show that open-labeled placebo was efficacious in reducing cancer-related fatigue and improving quality of life in fatigued patients with advanced cancer at the end of 1 week. The improvement in fatigue was maintained for 4 weeks (Abstract 12006).

Advertisement

Advertisement




Advertisement